Cormorant Asset Management’s Indaptus Therapeutics INDP Stock Holding History

Cormorant Asset Management’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-345	Closed	-$3.4M	–	66
2018 Q2	$3.4M	Hold	345	–	–	0.25%	52
2018 Q1	$4.89M	Sell	345 -17	-5%	-$241K	0.36%	42
2017 Q4	$4.17M	Hold	362	–	–	0.44%	40
2017 Q3	$7.25M	Hold	362	–	–	1.28%	27
2017 Q2	$4.62M	Hold	362	–	–	0.77%	39
2017 Q1	$4.14M	Hold	362	–	–	0.6%	44
2016 Q4	$4.62M	Hold	362	–	–	0.62%	43
2016 Q3	$4.76M	Hold	362	–	–	0.53%	52
2016 Q2	$3.72M	Buy	362 +5	+1%	+$44.9K	0.53%	50
2016 Q1	$3.3M	Hold	357	–	–	0.5%	49
2015 Q4	$4.29M	Hold	357	–	–	0.51%	46
2015 Q3	$4.48M	Buy	+357	New	+$4.69M	0.72%	40

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Cormorant Asset Management's INDP Position: Q3 2018 in Review

Cormorant Asset Management sold out of Indaptus Therapeutics (INDP) in Q3 2018, closing a stake of 345 shares — an estimated $3.4M sold.

Cormorant Asset Management first reported a position in INDP in Q3 2015 and held it in 12 quarters. The position peaked at $7.25M in Q3 2017. 25 funds tracked by Wall St. Rank hold INDP as of Q3 2018.

Cormorant Asset Management reported no remaining Indaptus Therapeutics position as of Q3 2018 after selling out during the quarter.
Cormorant Asset Management sold 345 Indaptus Therapeutics shares in Q3 2018, an estimated $3.4M.
Cormorant Asset Management first reported a position in Indaptus Therapeutics in Q3 2015 and held it in 12 quarters.
Cormorant Asset Management's Indaptus Therapeutics position peaked at $7.25M in Q3 2017.
25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2018.

Based on Cormorant Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.